(Q36723833)

15 August 2017

1 reference

title

New physiopathological and therapeutic approaches to diverticular disease of the colon (English)

1 reference

15 August 2017

Antonio Tursi

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

299-307

1 reference

Diverticulitis: when and how to operate?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Acute diverticulitis of the colon--current medical therapeutic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Mesalazine for diverticular disease of the colon--a new role for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Diverticular colitis: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

What is diverticular colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Segmental colitis: so what?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Medical therapy for ulcerative colitis 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Oxidants and free radicals in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Cytokines in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Efficacy of mesalazine in the treatment of symptomatic diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Probiotics for infectious diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Association between sigmoid diverticulitis and left-sided colon cancer: a nested, population-based, case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

Diverticular disease as a risk factor for sigmoid colon adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.3.299

21 January 2018

Identifiers

DOI

10.1517/14656566.8.3.299

1 reference

15 August 2017

1 reference